Hot attention: how to improve the current drug bidding procurement system?
Release time：2015-08-26
Author：
The successive introduction of No. 7 and No. 70 has outlined the basic outline of the general direction and rules of regulation and control for the future purchase of drugs in various places. With reference to the above-mentioned basic rules and combined with the actual situation of various regions, it has become a dynamic mode of a new round of online procurement to continuously absorb good local innovation experience and measures for nationwide integration and promotion.
Any policy and system has its positive aspects, but also some aspects that may be omitted or need to be further improved. Some thinking suggestions are also put forward from the perspective of industry and enterprises.
The fairness, rationality and scientificity of the recruitment catalogue.
Anhui, Fujian and other places have taken medical insurance, agricultural cooperation and basic drug products as the basis for the formulation of bidding and procurement catalogues, blocking all self-paid drugs. Document No. 70 also advocates that the recruitment catalogue should be based on the usage of the previous year. 80% of the products before usage enter the catalogue. The larger the usage, the easier it is to enter the catalogue. The premise of drug online procurement is fair and reasonable. Is it reasonable to completely cancel the online listing and sales qualification for new drugs and products that have not met the previous access conditions, failed to start sales and have just started sales? Medical insurance is adjusted every five years. Only when entering medical insurance and catching up with the Internet can we have the basic conditions for large sales volume. Just waiting for the threshold of market access, the sales volume in lucky areas will open in 3-5 years, while the unfortunate areas will need to survive the Anti-Japanese War for 8 years.
Although the original intention of the regulation and control plan designed by the state to increase the concentration of drugs and thus improve the ability to control prices is good, and it also provides some market support and encouragement policies for innovative drugs in the past two years, it is also necessary to pay attention to this part of the middle layer products that have not yet had time to enter the medical insurance catalogue, among which there are many products with better curative effect, safer and more cost-effective, At the same time, it is also welcomed and needed by medical institutions. Should the market-oriented operation give such products the same chance of survival, or should they all be expelled from the hospital by means of human intervention, and the old products in the hospital should be monopolized and sold?
If we talk about product innovation and substitution on the one hand, but in the process of entering the market, we use all kinds of artificial restrictions to stifle substitute products out of the arena, there is no fair competition at all, but also to encourage conformism. At the same time, it also brings a heavy burden of serious overspending and overdraft for the medical insurance department. More industries and enterprises caused tens of billions, hundreds of billions of yuan of serious investment losses, the pharmaceutical industry is facing a severe survival test of product dating. Reserving living space for self-paid drugs is also a useful supplement to medical insurance control fees, and the right to choose drugs is truly handed over to the market and patients.
The Price Meaning VS Quality Meaning of the Lowest Price Linkage
Even if the lowest price is collected, there are many specious places. Some enterprises price maintenance is very good, with the help of quality level or subtle differences brought about by the protection barriers, the national lowest price is still far higher than other enterprises of the same product national highest price, and can not reflect the product price competitive advantage in the network.
For other enterprises, on the contrary, the lowest price in the country is only the embarrassment encountered by enterprises due to quotation errors or malicious bidding in intensive bidding processing. Enterprises will not recognize it, will not supply it, and have no sales records at all. Similarly, they cannot represent the real sales price and operating costs of enterprises.
Some enterprises that have not been professionalized and popularized even think that this price enterprise cannot do it, so they give it to them. They do not supply goods in a big deal. They do not know what the low price does mean to the enterprise, and they do not know what the bid can be abandoned. In some areas, the full overlord clause can neither abandon the bid nor abolish the bid, and directly put the price that the enterprise cannot approve on the Internet.
The direct consequence of the lowest price linkage is that obviously the enterprise can still sell at a slightly lower price than the normal price in some areas, but due to the price linkage, the enterprise has no choice but to abandon the bid and can only stick to the price bottom line and abandon the operable market.
In the enterprise to hang the net price can not support the normal operation of the brain at the same time, product quality is often unable to be strictly guaranteed. The probability of shoddy, fake and inferior drugs increases. The problem of Ginkgo biloba preparation is also due to the lower and lower bid price, the higher and higher raw material cost, manufacturing cost and operating cost. Enterprises can only try their best to reduce the cost and cost.
Next Page
Next Page
Related News
2024/01/18
Mobile Web